AstraZeneca-Ionis drug fails to meet main goal in late-stage heart disease trial

AstraZeneca reported that Wainua (developed with Ionis) failed its primary endpoint in a late-stage trial, not achieving the target of reducing cardiovascular deaths and recurring heart problems. The miss increases risk around the program’s clinical and commercial outlook. Market impact is likely moderate as expectations for the late-stage readout are reset.

Analysis

AstraZeneca reported that Wainua (developed with Ionis) failed its primary endpoint in a late-stage trial, not achieving the target of reducing cardiovascular deaths and recurring heart problems. The miss increases risk around the program’s clinical and commercial outlook. Market impact is likely moderate as expectations for the late-stage readout are reset.